GT Biopharma(DE:OXI)
€119.250.00 (0.00%)
DE:OXI
GT Biopharma financials statements
€119.25
At close:0.00 (0.00%)
GT Biopharma (OXI) Ratios
0 Followers
GT Biopharma Ratios
DE:OXI's free cash flow for Q2 2026 was $-4.26M. For the 2026 fiscal year, DE:OXI's free cash flow was increased by $0.00 and operating cash flow was $-4.26M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.50 | 0.72 | 2.12 | 3.35 | 3.14 |
| Quick Ratio | 3.50 | 0.72 | 2.12 | 3.35 | 3.14 |
| Cash Ratio | 2.94 | 0.67 | 0.16 | 1.15 | 0.87 |
| Solvency Ratio | -12.23 | -2.23 | 0.90 | -4.18 | -5.65 |
| Operating Cash Flow Ratio | -5.57 | -2.19 | -1.33 | -3.08 | -1.52 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -503.42 |
| Net Current Asset Value | $ 5.79M | $ -1.67M | $ 7.42M | $ 11.56M | $ 21.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | -2.53 | 1.89 | 1.43 | 1.47 |
| Debt Service Coverage Ratio | -222.26 | 0.00 | 28.07 | -2620.63 | -76.74 |
| Interest Coverage Ratio | -97.81 | 0.00 | -63.74 | -2657.13 | -80.10 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.58 | 0.00 | 0.20 | 0.01 | 0.03 |
| Net Debt to EBITDA | 0.24 | 0.30 | -0.17 | 0.26 | 0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 228.26% | 91.63% | 55.96% | 98.25% | 100.87% |
| Return on Assets (ROA) | -349.79% | -311.01% | -53.85% | -124.78% | -180.34% |
| Return on Equity (ROE) | -489.96% | 788.14% | -101.62% | -177.98% | -264.78% |
| Return on Capital Employed (ROCE) | -214.65% | 860.12% | -181.59% | -180.17% | -262.51% |
| Return on Invested Capital (ROIC) | -214.65% | 860.12% | -180.20% | -178.51% | -262.13% |
| Return on Tangible Assets | -349.79% | -311.01% | -53.85% | -124.78% | -180.34% |
| Earnings Yield | -654.98% | -227.49% | -73.72% | -2.47% | -2.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -58.56 | -6.80 | -6.57 | -0.48 | -0.55 |
| Free Cash Flow Per Share | -58.56 | -6.80 | -6.57 | -0.48 | -0.55 |
| Dividend Paid and CapEx Coverage Ratio | -56.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -152.62 | -87.45 | -503.42 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -298.31% | -223.03% | -85.90% | -1.80% | -0.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.13 | -0.44 | -1.36 | -40.54 | -44.41 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.75 | -3.46 | 1.38 | 72.16 | 117.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.34 | -0.45 | -1.16 | -55.64 | -165.08 |
| Price-to-Operating Cash Flow Ratio | -0.34 | -0.45 | -1.16 | -55.64 | -165.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.02 | -0.00 | 0.60 | 0.65 |
| Enterprise Value Multiple | 0.09 | -0.14 | 1.55 | -40.13 | -44.67 |
| Enterprise Value | -2.48M | 1.83M | 9.28M | 841.23M | 2.57B |
| EV to EBITDA | 0.09 | -0.14 | 1.55 | -40.13 | -44.67 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.19 | -0.14 | -1.05 | -55.28 | -164.51 |
| EV to Operating Cash Flow | 0.19 | -0.14 | -1.05 | -55.28 | -164.51 |
| Tangible Book Value Per Share | 26.24 | -0.88 | 5.55 | 0.37 | 0.78 |
| Shareholders’ Equity Per Share | 26.24 | -0.88 | 5.55 | 0.37 | 0.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -128.57 | -6.94 | -5.64 | -0.66 | -2.06 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.46 | 0.98 | 1.17 | 0.73 | 0.27 |
Currency in USD
